This author undertakes an analysis of the cartels in the Pakistani pharmaceutical industry with the main aim of establishing the practice of cartelization of prices. In the present years, political and socioeconomic factors in the Pakistan's pharmaceutical sector can be analyzed in terms of regulation, competition, and market manipulation by cartels. This paper analyzes the nature and formations of cartels in this sector, the impact of the cartel on the prices of drugs, availability of the essential medicine, and consumers' welfare. To examine the effects of the cartel infliction in the pharmaceutical market and on the country's health care system, this paper adopts legal, economic and policy analyses. Therefore, this paper attempts to explore how effective Pakistan's current healthcare policy is in achieving its health objectives, compare its environment with other well-developed countries, and finally provide reforms that can lead to a healthier nation.
Keywords: Cartels. Pharmaceutical Sector. Price Fixing. Economic Impact. Pakistan. Market Regulation. Competition Law. Drug Prices. Regulatory Framework
1. Introduction
1.1 Historical Background and Origin
It can be stated that the development of the pharmaceutical industry in the context of Pakistan has been progressing during the recent decades and that it is an important segment of health care and economy in the region. The chapter under discussion highlights the overview of the Pakistan's pharma industry that forms one of the largest and rapidly growing industries of the developing world for production of domestic as well as export requirement of medicines to different countries. Nevertheless, this important industry has suffered from market abuse through the cartelization, especially on the issues affecting drug costs. Cartels in this scenario are groups of pharmacy and related industries engaging in a conspiracy to control the prices and limit entry of new competitors to the markets after their convergence with promising beneficial terms which to the disadvantage of consumers and the overall health system.
In the pharmaceutical sector, the problem of price fixing and some other restrictive activities have been observed often in Pakistan with cooperation of government and other regulatory bodies. The subject of cartels has, however, attracted much attention due to the rising prices of essential medicines that have thus affected the health sector especially to the low-income earners. Pharmaceutical cartels in the context of Pakistan have over the years worked in legal ambiguity as there was very little compliance of competition laws and regulatory requirements due to negligible oversight and unestablished and weak enforcement.
1.2 Origin and Development of Pharmaceutical Cartels in Pakistan
For an appropriate understanding of the genesis of cartel formation in the pharmaceutical sector of Pakistan, one needs to look at the structural development in the country's economy and its regulating framework. In the beginning, the government of Pakistan did not intervene directly based on the belief that the market forces would act as the best regulators of the market. This resulted to alter the situation where the pharmaceutical industries especially those companies within the generic drug industry had the leverage to determine the drug prices. The absence of well-developed competition laws complemented by the general ignorance of the possible social impacts of the cartel behavior resulted in the manifestation of cartel schemes such as the collusion regarding price and the division of the market share which are contrary to the notion of fair competition.
In the last decade of the twentieth century, and in this technologically activated twenty-first century, various other arbitration councils used to know as Drug Regulatory Authority of Pakistan (DRAP). Nevertheless, cartel behavior has remained prevalent in some parts of the pharmaceutical market, particularly, with respect to products and medicines where consumers and patients have limited options, and the drugs involve are vital to human life. It has also become even worst through the years especially with the dawn of multinational pharmaceutical companied and their influence on most legislatures around the globe.
1.3 Objectives of the Study
Therefore, there are the following research objectives: Analyse the nature of Cartels in Pakistan's pharmaceutical industry — Understand how the cartels in the existing pharmaceutical field are structured and what might explain the sustainability of the cartel like formation in the sector. Price Fixing process in the Pharmaceutical Sector — Identify the workings of price-fixing cartels, its tactics, and procedures used to regulate drug prices. Assess the Economic Impact of Cartel Behavior on Drug Prices — Evaluate the effect of price-fixing on the affordability and accessibility of essential medicines in Pakistan. Screen the Legal & Compensational Perspective — Assess the laws and policies that exist in the current market to curb cartels and promote fair competition in the pharmaceutical market.
1.4 Significance of the Study
The importance of this research is that it will give the information concerning the problem being caused the cartel in the Pakistan's pharmaceutical industry and its effects on the whole economy. The specificity of the study topic, which is cartel conduct and price fixing, will enable the investigation of the impact of these anti-competitive practices on the availability of medicines for the Pakistani population and especially the vulnerable population as well as on the health sector in Pakistan. This research will be very useful to extend the literature on the competition law and market regulation in Pakistan and provide appropriate knowledge to the policy makers about the economic impacts of cartel. In addition, it will offer specific suggestions for a better enforcement of the anti-cartel laws, protection of fair competition, and free access of medicines to the public. It may be useful for government authorities, healthcare facilities, pharmaceutical corporations, and customers of the drugs worldwide but particularly in Pakistan to promote a fair and effective market structure in the country. By covering this question, the research also relates to global discussions on the necessity of fighting cartels in the civilised spheres, including healthcare, when the effectiveness of the economy and human life is at stake.
2. Literature Review
2.1 Introduction to Cartels and Price Fixing
Cartels are associations of independent business firms in a formal and legal way or informally to organize themselves with the motive to control the market and its condition for their own benefits mainly in the formats of price, production or market share. In most industries, cartels are regarded as undesirable, especially in as far as competition is concerned and consumer protection is concerned. When it comes to the operation of cartels in the pharmaceutical sector, they tend to affect the market through fixing the prices of drugs, this has the effect of distorting competition and placing a fair standard of escalating prices for the drugs. Criminals engage in an anti-competitive practice popular known as price fixing where firm's cartel and agree on what they should offer a certain good or service for instead of offering their services to the market where prices are set by supply and demand. Such behavior although hidden can cause a lot of harm to the consumer, particularly in the health sector dealing with products such as drugs which are necessities. Thus, the issues related to cartel activities that are often associated with the strengthening of the pharmaceutical industry in developing countries resulted in complex regulatory environment, high inconsistency of the enforcement and problems with price-fixing appeared in the Pakistani pharmaceutical sector. These activities have negative economic impacts for consumer and the general economy.
2.2 Cartel Formation in the Pharmaceutical Sector
For this reason, the pharmaceutical industry, especially on the international level, is particularly vulnerable to cartel formation because the market is characterized by a few large firms. In this regard, Pakistan has also witnessed such practices especially in form of vertical agreements pertaining to fixing of prices where the vicious circle in act is the pharmaceutical companies. Iqbal (2019) notes that a concerted action in Pakistan's pharmaceuticals space usually occurs through exchange of information between key firms. This makes it possible for these companies to put forward their prices in a manner that will not put them in competition with another. Thus, there is an absence of adequate supervision and something very important, regulation and its enforcement here fulfillment of these lacks. In many studies, the government regulations and the regulatory authority, DRAP, have working and their functioning has been discussed. The duties of DRAP include regulating prices of drugs to ensure that they are reasonable and to prevent anti-takeover strategies by manufacturing companies of necessary drugs. However, other authors like Ahmed & Saleem (2020) reveal that inability to develop capacity to monitor the market and enforce the regulations has led to this vice by cartels. There is a presence of cartels, especially in the pharmaceutical segment with moderate threat of new entrants due to the high industry growth. The rationale for this is due to the reality that new entrants have difficulties of competing with well-established firms that can combine high levels of financial and operational capacities to exert pressure on prices as noted by Zaman et al (2021). This helps to reduce competition and adds onto the effects caused by price-fixing hence being unbeneficial in the community at large.
2.3 Market Issues of Price Fixation with Specific Focus on the Pakistan Pharmacy Sector
The problem of excessive price control in regard to the Pharma industry is a major concern in Pakistan also. It first should be noted that the government regulates the prices of drugs, especially essential ones, putting a cap on certain medications prices. Price control, which is usually aimed at safeguarding consumers, tends to lead to situations where firms are provoked into an agreement for the objective of evading the controls. Saad et al., (2018) also highlighted that the pharmaceutical cartel in Pakistan was involved in the secret adjustment of prices in their study. Most of these firms consent to sell the essential medicines at a higher price as compared to the price list developed by the DRAP. In an average new competition setup, manufacturers, wholesalers and retailers engage in the cartel like agreement that helps to enhance the drug prices but at the same time, the outside perception remains that competition is ever raging. A major concern of price-fixing is the issue of access to health products both in the developed and the developing world, particularly in the pharmaceutical sector. WHO (2020) established that the health implication of crossing prices based on cartel formation is that consumers find it hard to afford necessary medicines. Which is equally big problem in low and middle-income countries like Pakistan where a large chunk of the population seeks subsidized healthcare services. Moreover, several studies have also revealed that pharmaceutical cartels do not confine their practices to branded products but rather to the generic products which are cheaper substitutes for branded products. Each of the manipulations made at both categories reduces the bargaining power of the people and increases costs on the average household expenses. Khan and Javed (2017) noted that this issue of price manipulation has affected the market for generic medicines has gone a long way to make medicines scarce thereby affecting the health of the public.
2.4 Economic Impact of Cartelization on Pakistan's Pharmaceutical Sector
The effects of cartelization on the economic welfare of the people are not only limited to the people who use the health facility as have been mentioned above. It is worth mentioning that there are other economic consequences of fixing prices in global industry that have also been supported by other authors. First, price-fixing practices, restrict market competition, and reduce the incentive for innovation. Pharmaceutical firms are inclined more on increasing their profit margins by hiking on the price of their products rather than investing in the R&D. According to Rasheed and Khan (2019), low competition mean that the firms do not invest in new and cheaper treatment methods. This means that there are limited options of innovative drugs in the market and such a move may slow down the quality of services being offered by healthcare organizations to the people. Furthermore, self-medication incurs revolutionary costs therefore bearing the brunt increase drug prices affects the low-income earners and those with harmful health insurance coverage. In a study done by Ali and Shah (2020), they estimated that pharmaceutical cartels in Pakistan negatively affect the buying of medicines by resulting to out-of-pocket expenditure. This leaves households in a very precarious position when it comes to meeting their financial needs hence increasing the levels of indebtedness among a large section of the population. The increasing cost of the healthcare budget also amplifies inequality in Pakistan because a significant portion of the population cannot afford adequate health-care services and medicines as compared to the higher social class. In addition, there are other consequential impacts of the price fixing in the pharmaceutical sector that will have an unfavorable impact on public health. And when drugs are too expensive, patients are willing to discontinue the course of the treatment regimens prescribed to them which in the long run leads to worsen health status hence, high total health costs. In line with Rahman (2021), expensive medicines, if not available or unaffordable to treat illnesses, have long-term consequences on the overall healthcare circuit in Pakistan; hence, enhancing public health services and the economy.
2.5 Regulatory Responses and Challenges
On this account, the impact and effectiveness of regulatory bodies for combating cartels has remained a centre of research interest in the context of Pakistan's pharmaceutical industry. The CCP stands for Competition Commission of Pakistan, and this authority mainly engage in anti-cartel exercises as advertised under Pakistan's competition laws. A few researchers have raised issues on the role of the CCP in combating cartel conduct in the pharma industry. However, there are a couple of concerns where lack of resources, institutional support and political interferences have been cited as a major bottleneck to the IPO in conducting efficient investigation and enforcing anti-cartel laws that are within its jurisdictions. Furthermore, there are concerns on how DRAP have implemented certain regulations. According to Ahmed (2020), one of the reasons that DRAP have failed to manage the cartel situation in the market is that it has lacked the capacity to monitor the market prices control policies implemented by various firms within the industry. However, the processes of price ceiling regulation in most cases do not protect consumers from possibly exorbitant price increases by the Drug Industries because the industries adjust prices in more concealed manners through such methods as changes of packaging sizes and the imposing of layers of markups along various stages involved in drug distribution. The legal provisions on handling the issues of price-fixing and cartel activities had long been developed beforehand. Nevertheless, there is a significant problem with the implementation of those laws, including legal capacities' scarcity, general inefficiency of inter-agency cooperation, and a rather feeble judicial response to cartel activities that is slow-moving at best. According to Zafar et al. (2018), to deal with this problem of cartels that is increasing in the pharmaceutical sector of Pakistan there is need for legal and regulatory reforms.
Existing literature on cartel in Pakistan medicines cites that hence, through thwarting the competitive forces of the market, influencing the price hiking of the essential commodities where quality health care is highly compromised. It acts as an instrument used in distorting market efficiency, leading to increased negative health impacts on the populace and widening income gaps. There are several obstacles to implementing anti-price fixing measures in the context of the regulatory environment in Pakistan and it was found that even though, legal norms and institutions already exist, the problem of their implementation is paramount. The future research should be directed on enhancing the effectiveness of the anti-cartel measures, on the explanation of the specifics of cartelization processes in various segments of the pharmaceutical market, as well as on the investigation of the other ways of drugs' prices and their accessibility for different population segments. The analysed literature shows that price fixing and cartel behavior in the context of Pakistani pharmaceutical sector should be addressed for proper pricing and encouraging innovation and better health in Pakistan.
3. Research Methodology
This research methodology explains the approach and instruments applied in probing cartel engagements and price fixing within Pakistan's pharmaceuticals industry alongside its economic impact. This paper sought to assess the legal, economic and regulatory implications of the given phenomenon of price increase in the pharmaceutical sector and its implication to its consumers and the entire economy. The present research work adopted a quantitative research approach whereby statistical tools were used to test the findings collected through surveys to determine the degree of price fixing in this sector. The type of research used in this study to assess the nature and prevalence of cartelization in the pharmaceutical industry of Pakistan was a descriptive research design. Information was collected on pharmaceutical companies, their actions and consequences related to their actions namely pricing strategies in the pharmaceutical market. This design was designed in a way that will be able to solicit empirical data from different clients who deal with or are affected by the operations of the pharmaceutical sector in the country in terms of suppliers, distributors, firms and consumers.
The technique of data collection applied in this study was surveys. A closed structured questionnaire was designed to obtain both quantitative and qualitative responses. Closed-ended questions captured basic quantitative data — the rate at which some products within the pharmaceuticals sector are liable to experience a hike in their prices, the percentage of pharmaceutical firms involved in price-fixing, the effect of price-fixing on business activities, and the potential effects of cartel operations on consumers and the public. Open-ended questions invited respondents to express experience or view, for instance the impact of price fixing practices on the availability of medicine, and the regulatory action considered appropriate to prevent cartel activity. The target population included employees working in the pharmaceutical sector of Pakistan including manufacturing companies, distributors, retailers, and the consumers directly affected by drug prices. The questionnaires were filled by at least 300 respondents, and stratified random sampling was employed to have a quasi-equal number of samples from the different areas of population, stratified by industry role, regional location, and experience in the sector. The survey data were processed using statistical software, applying descriptive statistics, inferential statistics, Chi-square tests, and regression analysis, and the study observed the required ethical considerations of informed consent, confidentiality and voluntary participation.
4. Results, Analysis and Discussion
The target population for this study was drawn from three groups of respondents including Pharmaceutical Companies, Distributors, and Consumers out of which 300 were selected: 100 respondents from Pharmaceutical Companies, 80 respondents from Distributors, and 120 respondents from Consumers. In terms of their involvement in cartel activities: 60 pharmaceutical firms said that they were involved in price-fixing; 40 distributors had knowledge of price-fixing activities; and 100 consumers testified that they have been affected by this vice through price-fixing.
On the frequency of price fixing, it was found out that about 70% had been pushed into frequently raising their prices due to cartels. More than half of the respondents disclosed that price fixing detracted from their ability to conduct business profitably as it created additional expenses. Majority of the consumers stated that because of price fixing, the prices of medication have become high and out of reach, implying that it has added more burden to the people. Respondents suggested that government intervention, vigorous monitoring, and enforcement of price controls with fines given to offenders could assist in eradicating such practices.
Using descriptive statistics, as for the frequency to fix prices, more than 60% of the companies confessed about the price-fixing practice at least once a month. On the economic effects, 80% of the respondents recorded negative effects on the market share of medicines and the state of public health, including increased prices for medications and their less availability. For inferential statistics, a Chi-Square test was used to test the relationship between cartel behaviour and its perceived impact on the consumers. It emerged that there was a high significance between the presence of price fixing among the pharmaceutical firms and the effect on the consumer's economy; the analyses revealed a p-value of 0.03 indicating that price fixing had a significant impact on the affordability of medicine to the consumers. Consequently, one can assert that cartel conduct is a major factor contributing to the recent increased cost of drugs, which has reached the consumers.
The following conclusions can be made from the analysis: Pharmaceutical Companies and Distributors are both closely implicated in price-fixing schemes; Consumers are the most affected by the economic harm, many of the respondents mentioning that the cost has reduced the availability of essential medications; and Regulatory action seems to be required as the respondents opined that government intervention and increased enforcement could reduce the negative impacts of the formation of price-fixing cartels. All these indicate that there is need to have policies against cartels particularly in the pharmaceutical industry to protect consumers and guarantee access to the products.
5. Recommendations
Strengthening Regulatory Enforcement. The study reveals a high incidence of price-fixing, so current regulatory structures might not be strong enough. Government and institutions like DRAP need to be allowed to periodically visit and scrutinize the pharmaceutical firms and distributors to check their prices. Increase the legal penalties for such cartels where legal punishment entails fines and business closures, which could serve as an effective deterrent. Structure a culture and legal landscape in which employees or other industry players can report cases of unethical pricing practices; protection for whistleblowers is beneficial for increasing the number of exposed unlawful actions.
Increasing Transparency in Pricing. Increase the affordability of pharmaceutical products through regulation of prices; all products available in the market should come with their price details. Releasing information on the price of basic medicines can eliminate monopolistic actions because customers can then compare prices from different companies and products. Undertake awareness creation exercises to enable consumers to know their rights on overpricing, how to report it and how to confirm the truth of the price of pharmaceuticals.
Improving Competition. Liberalize the market place by creating room for other players, especially local producers of pharmaceutical products, to check the monopolistic price control by cartels; stringent measures such as high entry barriers and restricted market access for small companies can contribute to the occurrences of cartels. Actively encourage the usage of generic drugs by offering incentives for manufacturers to produce substitute drugs to the expensive branded ones, which would extend beneficial variety to consumers and increase competition, leading to a decrease of prices.
Strengthening International Collaboration. Pakistan must engage the World Health Organization (WHO), International Competition Network (ICN), and other recognized global regulatory agencies to learn best practice on anti-cartel enforcement and price control. In order to avoid situations when pharmaceutical companies manipulate prices based on import-export policies, collaborate with neighboring countries to set up a cross-border price-indexing system.
Expanding Research and Data Collection. More and better research needs to be conducted to have more updates in the pricing systems and detect more cartels, so that regulators would be able to promptly address any potential pricing troubles. Employ big data, data analytic systems, and artificial intelligence (AI) to identify price-indication cartels as it happens, increasing efficiency in the detection of unlawful activities.
Consumer Protection Policies. Encourage the provision of subsidies so that essential drugs can be purchased at reasonable prices for the average population, shielding consumers from high costs emanating from cartel practices. The government should also consider the betterment and expansion of medicine availability at an affordable price across the country, including in rural sparsely populated areas — mobile stores for medicines or online prescribing and dispensing platforms may be part of these. In addition, design autonomous means through which the efficacy of the anti-cartel policies can be assessed over time, and adopt an easy way through which consumers can report any issue with the price of any pharmaceutical product or any suspected foul play. Through Corporate Social Responsibility (CSR) initiatives and Public-Private Partnerships (PPP), pharmaceutical companies should be encouraged to adhere to fair business practices that promote affordable health care and access to medicine.
Conclusion
To combat cartels in the context of Pakistan's pharmaceutical sector, it requires better regulation, better competition policies, high degree of transparency, and protection to the customer. Preventing the current laws from being violated and enhancing the new methods of price controlling can substantially narrow cartel's power and equity in the selling market. This is why it is important to have a close cooperation between the government, pharmaceutical manufacturing industries and the international trips agreements authorities. For many years, Pakistan has been suffering from the effects of cartels that have blighted the pharma sector which bears significant importance to the health care system of the country. Based on the analysis of the tendencies concerning the cartels, the changes in the market and the flaws of the regulations, it can be stated that they are one of the key factors that contribute to high drug prices and limited availability of necessary medicines for millions of citizens.
The initial and most obvious fact is the lack of implementation of the currently existing policies. With the establishment of Pakistan's Drug Regulatory Authority (DRAP), the authority has made reasonable progress in checking drug prices though the rate of enforcement is still low in decimating cartels. The research calls for increased autonomy of the regulatory authorities as well as providing them with proper means and resources for controlling the actions of the pharmaceutical companies. The severe penalties for the offenses of price fixing must be coupled with an independent auditing system to strengthen the level of deterrence against colluding pharmaceutical cartels. High levels of opacity in pricing must be addressed by ensuring that the prices of all important medicines are declared publicly. Market competition driven by entrants of additional domestic firms can help in combating cartel influence, and cooperation with global entities such as the WHO and ICN will curb the ability of organisations to use cross-border supply chains to manipulate prices. Adequate data collection and research, together with consumer protection policies such as subsidies for essential and life-saving medicines, are vital. By improving the regulatory approach, increasing the transparency of the industry, increasing competition within the market, and seeking the development of international cooperation strategies, it will be possible to achieve a new balance in the pharmaceutical market that puts the needs of its populace before its need for profits.